Literature DB >> 28847224

Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747).

Terry J Smith1, Joseph A M J L Janssen2.   

Abstract

Entities:  

Year:  2017        PMID： 28847224      PMCID： PMC5672619          DOI： 10.1089/thy.2017.0281

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  6 in total

1.  TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

Authors:  Christine C Krieger; Susanne Neumann; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  Thyroid       Date:  2017-03-27       Impact factor: 6.568

2.  Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

3.  Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor.

Authors:  Jane Pritchard; Shanli Tsui; Noah Horst; William W Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

4.  Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.

Authors:  Shanli Tsui; Vibha Naik; Neil Hoa; Catherine J Hwang; Nikoo F Afifiyan; Amiya Sinha Hikim; Andrew G Gianoukakis; Raymond S Douglas; Terry J Smith
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

5.  Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.

Authors:  Jane Pritchard; Rui Han; Noah Horst; William W Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

Review 6.  Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-03       Impact factor: 5.555
  6 in total
  7 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  Rebuttal to Smith and Janssen (Thyroid 2017;27:746-747. DOI: 10.1089/thy.2017.0281).

Authors:  Susanne Neumann; Marvin C Gershengorn
Journal:  Thyroid       Date:  2017-10-17       Impact factor: 6.568

3.  Modulating TSH Receptor Signaling for Therapeutic Benefit.

Authors:  Gerd Krause; Anja Eckstein; Ralf Schülein
Journal:  Eur Thyroid J       Date:  2020-11-23

4.  Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.

Authors:  Roshini Fernando; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

5.  Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases - Why Not This One?

Authors:  Amy M FitzPatrick
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

6.  Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.

Authors:  Bernice Marcus-Samuels; Christine C Krieger; Alisa Boutin; George J Kahaly; Susanne Neumann; Marvin C Gershengorn
Journal:  Thyroid       Date:  2018-04-30       Impact factor: 6.568

7.  It takes two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.

Authors:  Leonard Girnita; Terry J Smith; Joseph A M J L Janssen
Journal:  J Clin Endocrinol Metab       Date:  2022-02-15       Impact factor: 6.134
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.